November 07, 2011 10:08 ET

Central Nervous System (CNS) Disorders Therapeutics Market to Reach $59 Billion by 2017

ROCKVILLE, MD--(Marketwire - Nov 7, 2011) - has announced the addition of the new report "Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010," to their collection of Diseases & Conditions market reports. For more information, visit

The report covers the overall global CNS disorder therapeutics market for the eleven indications including: Alzheimer's disease, multiple sclerosis, Parkinson's disease, diabetic neuropathy, major depressive disorder (MDD), bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD), and migraine. The market reached $53.1 billion in 2010, compared to $36.8 billion in 2002, growing at a CAGR of 4.7%.

The market is expected to witness fluctuations as a result of patent expiries followed by generic erosion and it will experience slow growth at a CAGR of 1.4% between 2010 and 2017, reaching $58.6 billion. Rising geriatric population all over the world, increased life expectancy, along with anticipated launch of novel molecules will drive the growth of CNS disease market in future.

The market for Alzheimer's disease and multiple sclerosis is expected to witness a significant growth due to expected launch of promising molecules with disease modifying characteristic and novel mechanism of action.

Patent expiries in recent and upcoming years are the only barrier to the global CNS disorder therapeutics market. Expected launch of novel molecules with disease modifying characteristic and better safety and efficacy will drive the market in forecast period.

The report includes:

  • Data and analysis on the CNS disorder therapeutics market in the leading geographies of the world -- the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the CNS disorder therapeutics market from 2002 to 2010, with forecasts to 2017.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Share of the generics in global CNS disorder therapeutics market and for the market of each indication that is covered in the report.
  • Key drivers and restraints that have had a significant impact on the market.
  • The competitive landscape of the global CNS disorder therapeutics market including top companies benchmarking. The key companies studied in this report are Eli Lilly, Pfizer, AstraZeneca, Teva, and Johnson & Johnson.
  • Key M&A activities and Licensing Agreements that took place in 2009 and 2010 in the CNS disease market.

For more information, visit

About is the leading provider of global market intelligence products and services. With over 300,000 research reports from more than 700 top consulting and advisory firms, offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. For more information, call Veronica Franco at 240-747-3016 or visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact